# B2B Licensing Playbook Licensing separates IP ownership from operational execution. In deep tech materials, a licensing model lets the innovator capture value across multiple industries and geographies without building manufacturing operations in each. The licensed asset is not just the patent — it is the entire commercialisation stack. ## What You Are Actually Licensing Most founders think they are licensing a patent. Sophisticated licensees want three things: 1. **The right to use the IP** — freedom to operate under the patent 2. **The regulatory dossier** — the approval package (GRAS file, BPR dossier, FCM safety data) that lets them make claims. This is often worth more than the patent itself; it represents years and millions of spend that the licensee does not have to repeat 3. **Application know-how** — the formulation, processing parameters, and performance data that makes the material work in their specific substrate and manufacturing environment License the first without the second and third, and the licensee will struggle to deploy. License all three and you create a recurring services relationship that extends well beyond the patent term. ## Four Licensing Archetypes ### Royalty per Unit A percentage of the licensee's revenue from products containing the licensed ingredient, or a fixed fee per kilogram of active substance purchased. Aligns incentives — the licensor benefits when the licensee succeeds — but requires auditable sales data and creates ongoing friction around royalty reporting. Best for: large licensees with transparent sales processes; situations where market size is uncertain and the licensor prefers upside exposure over upfront certainty. ### Upfront Licence + Milestone Payments A lump sum at deal close (immediate value capture), followed by payments tied to defined events: regulatory approval received, product launch, first-year revenue threshold. The milestones shift risk to the licensee to execute. Best for: licensors who need capital now; situations where regulatory timelines are long and the licensor wants the licensee committed before approval. ### Exclusive Territory Licence The licensee receives exclusive rights in a defined geography or market segment in exchange for a premium price. Exclusivity commands 2–5× the royalty rate of a non-exclusive deal. The critical risk: an underperforming exclusive licensee blocks the licensor from the market entirely. Mitigation: include minimum purchase obligations (minimum annual royalties or minimum volume commitments) with automatic conversion to non-exclusive if the licensee fails to hit thresholds. ### Cross-Licence Both parties exchange IP portfolios — relevant when the licensee holds complementary patents (e.g., a specific delivery mechanism or polymer processing technology). Cross-licences resolve freedom-to-operate issues and can accelerate market entry for both parties. ## Key Leverage Points in Negotiation **Regulatory approval as non-replicable infrastructure.** The licensor who holds an EFSA opinion or FDA GRAS determination controls the fastest path to market. No amount of money buys time when the regulatory clock requires sequential steps. **Exclusivity windows with performance triggers.** Grant exclusivity for 24–36 months, subject to the licensee achieving volume milestones. If they miss milestones, exclusivity converts to non-exclusive — protecting the licensor from a blocking position. **Field-of-use restrictions.** A licence limited to fresh produce packaging does not prevent the licensor from separately licensing the same material for HoReCa disinfection or pharmaceutical applications. Field-of-use carve-outs are standard in materials licensing. **Layered IP.** Patent protection covers the composition. Trade secrets cover the formulation parameters and application know-how. Know-how is licensed separately, with confidentiality obligations that survive patent expiry. This extends the effective protection period beyond the 20-year patent term. ## The Design-Around Risk The principal risk in any licensing arrangement: the licensee learns enough from the licensed know-how to engineer around the patent and replicate performance with a non-infringing variant. Mitigations: - Build claims broad enough that design-around requires significant performance sacrifice - Include trade secret provisions with non-circumvention language - Maintain a continuing R&D programme that generates improvements, each of which can be offered as an improvement licence — keeping the licensee dependent on the licensor's R&D pipeline --- *Part of [[Natural Antimicrobials & Sustainable Materials MOC]]*